Mental Disorders Now Leading Cause of Disability Worldwide, Ahead of Heart Disease and Cancer

IMT News Desk
IMT News Desk
· 3 min read
Mental disorders now surpass heart disease and cancer as the leading cause of disability worldwide, with youth and women most affected, study finds.

Mental disorders have more than doubled globally since 1990 and are now the leading cause of disability worldwide, overtaking cardiovascular disease, cancer and musculoskeletal conditions, according to a new analysis published in The Lancet. The study estimates that nearly 1.2 billion people were living with a mental disorder in 2023, with anxiety and depression driving much of this surge and young people and women carrying a disproportionate share of the burden.

Researchers from the University of Queensland, the Queensland Centre for Mental Health Research and the University of Washington analysed Global Burden of Disease 2023 data for 12 mental disorders, including anxiety, major depression, bipolar disorder, schizophrenia, autism spectrum disorders, ADHD and eating disorders. Mental disorders accounted for over 17 per cent of all years lived with disability in 2023, making them the single largest contributor to non-fatal health loss across countries, regardless of income level or health system strength.

The gender and age patterns are particularly stark. In 2023, about 620 million women were living with a mental disorder compared with 552 million men, with women showing higher rates of anxiety and depression, while boys and young men were more affected by neurodevelopmental and behavioural disorders such as ADHD, conduct disorder and autism. The global burden peaked in the 15- to 19-year-old age group, underscoring the need for early prevention, school- and community-based interventions and youth-focused mental health services.

India reflects and amplifies some of these trends. The age-standardised prevalence of anxiety disorders across both sexes rose from roughly 2,592 per 100,000 population in 1990 to about 5,793 per 100,000 in 2023, an increase of 123.5 per cent. Among women, anxiety prevalence climbed by 136.7 per cent over this period, compared with a 102 per cent rise among men, pointing to a widening gender gap in mental health needs and the urgency of integrating gender-sensitive approaches into national programmes.

Experts behind the study link these rising trends to both the lingering effects of pandemic-related stress and deeper structural drivers such as poverty, insecurity, abuse, violence and eroding social connectedness. They warn that current responses remain inadequate and call for sustained investment in mental health systems, expanded access to timely and affordable care, and stronger surveillance, especially in low- and middle-income countries, to track needs and outcomes. A 2025 World Health Organization analysis of global health estimates similarly found that more than 1 billion people were living with a mental health condition in 2021, with anxiety and depressive disorders accounting for about two-thirds of all cases, reinforcing the case for treating mental health as a core public health priority rather than an afterthought.

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk